Evidence map›Paper›PMID 30994574›Full record

ArticleMenopause (New York, N.Y.)2019

Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy.

Caroline S Dorfman, Sarah S Arthur, Gretchen G Kimmick, Kelly W Westbrook, Paul Kelly Marcom, Cheyenne Corbett, Sara N Edmond, Rebecca A Shelby

Open access · greenAbstract read
In one paragraph

Article in Menopause (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Clinical Practice Strategies to Address Sexual Health in Female Cancer Survivors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Caroline S DorfmanDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC.
Sarah S ArthurDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC.
Gretchen G KimmickDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC.
Kelly W WestbrookDivision of Medical Oncology, Duke University, Durham, NC.
Paul Kelly MarcomDivision of Medical Oncology, Duke University, Durham, NC.
Cheyenne CorbettDuke Supportive Care and Survivorship Center, Duke University, Durham, NC.
Sara N EdmondPain Research, Informatics, Multimorbidity & Education (PRIME) Center, VA Connecticut Healthcare System, West Haven, CT.
Rebecca A ShelbyDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC.
Duke University · USDuke Medical Center · USVA Connecticut Healthcare System · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8M
Improving Adherence to Recommended Surveillance in Breast Cancer SurvivorsK07CA138767 · NCI · DUKE UNIVERSITY · PI SHELBY, REBECCA A · 2010 to 2014
$788k
NCI NIH HHS K07 CA138767NCI NIH HHS P30 CA014236
6 · The paper itself

Abstract

objectivePast studies indicate that >90% of breast cancer survivors taking adjuvant endocrine therapy (AET) experience menopausal symptoms including sexual problems (eg, vaginal dryness, dyspareunia); however, research examining the impact of these problems on quality-of-life is limited. This cross-sectional study examined (1) the impact of sexual problems and self-efficacy for coping with sexual problems (sexual self-efficacy) on quality-of-life (ie, psychosocial quality-of-life and sexual satisfaction), and (2) partner status as a moderator of these relationships.

methodsPostmenopausal breast cancer survivors taking AET completed measures of sexual problems (Menopause-Specific Quality-of-Life [MENQOL] sexual subscale], sexual self-efficacy, psychosocial quality-of-life (MENQOL psychosocial subscale), and sexual satisfaction (Functional Assessment of Cancer Therapy-General item).

resultsBivariate analyses showed that women reporting greater sexual problems and lower sexual self-efficacy had poorer quality-of-life and less sexual satisfaction (all P-values < 0.05). Partner status moderated the relationship between sexual problems and psychosocial quality-of-life (P = 0.02); at high levels of sexual problems, unpartnered women experienced poorer psychosocial quality-of-life than partnered women. Partner status also moderated the relationship between self-efficacy and psychosocial quality-of-life (P = 0.01). Self-efficacy was unrelated to psychosocial quality-of-life for partnered women; for unpartnered women, low self-efficacy was associated with poorer quality-of-life. Partner status did not moderate the relationships between sexual problems or self-efficacy with sexual satisfaction.

conclusionsGreater sexual problems and lower sexual self-efficacy were associated with poorer psychosocial quality-of-life and sexual satisfaction among postmenopausal breast cancer survivors taking AET. Interventions to address sexual problems and sexual self-efficacy, particularly among unpartnered women, may be beneficial for improving the well-being of postmenopausal breast cancer survivors on AET.

Indexed as

Self EfficacyAgedAntineoplastic Agents, HormonalAromatase InhibitorsBreast NeoplasmsCancer SurvivorsChemotherapy, AdjuvantCross-Sectional StudiesFemaleHumansMedication AdherenceMiddle AgedPostmenopauseQuality of LifeSexual BehaviorSexual Dysfunction, PhysiologicalAntineoplastic Agents, HormonalAromatase InhibitorsTamoxifen

Identifiers

PMID30994574
PMCPMC7081279
OpenAlexW2940780087

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.